NBIX
NEUROCRINE BIOSCIENCES INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$136.98
+0.94%Year over year
Reported trailing growth
- Revenue
- +34.4%
- EBITDA
- +60.8%
- EBIT
- +59.4%
- EPS
- +102.6%
- Free cash flow
- +64.6%
- Operating cash flow
- +58.3%
Forward estimates
Based on analyst estimates
- Revenue
- +32.8%
- EBITDA
- +49.5%
- EPS
- +29.8%
Three-year CAGR
- Revenue
- +24.3%
- EBITDA
- +41.2%
- EBIT
- +35.5%
- Net income
- +45.8%
- EPS
- +44.0%
- Free cash flow
- +32.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026